Journals / Türk Mikrobiyoloji Cemiyeti Dergisi / 2022 / Cilt: 52 - Sayı: 1

Seroprevalence of Cytomegalovirus (CMV) IgG and IgM Antibodies in Pregnant Women in Izmir: An Analysis of CMV IgG Avidity Tests

İzmir İlinde Gebelerde Sitomegalovirüs (CMV) IgG ve IgM Antikorlarının Seroprevalansı: CMV IgG Avidite Testlerinin Analizi

Pages
56–62
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With the establishment of an effective national surveillance network, additional measures can be applied in the follow-up of pregnant women by expanding the scope of seroprevalence studies with continuously updated data by region and year.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to determine the seroprevalence of cytomegalovirus (CMV) in pregnant women in İzmir province and to evaluate CMV IgG antibody levels and CMV avidity test results according to years.
📊
Key Findings & Data:Methods: CMV IgM, CMV IgG and CMV IgG avidity tests were performed using the chemiluminescence microparticle immunoassay method in serum samples from pregnant women(≥18 years, ≤20 gestational week) at the microbiology laboratory of university hospital from January 2016 to December 2019 and results were retrospectively analyzed.
💡
Conclusion & Impact:With the establishment of an effective national surveillance network, additional measures can be applied in the follow-up of pregnant women by expanding the scope of seroprevalence studies with continuously updated data by region and year.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to determine the seroprevalence of cytomegalovirus (CMV) in pregnant women in İzmir province and to evaluate CMV IgG antibody levels and CMV avidity test results according to years. Methods: CMV IgM, CMV IgG and CMV IgG avidity tests were performed using the chemiluminescence microparticle immunoassay method in serum samples from pregnant women(≥18 years, ≤20 gestational week) at the microbiology laboratory of university hospital from January 2016 to December 2019 and results were retrospectively analyzed. Results: The mean age of 3062 pregnant women included in the study was 28.57±5.96(range: 18 - 48 years) years. The CMV IgG and IgM seropositivity rates were 94.22% (n=2885) and 1.37% (n=42), respectively. CMV IgG avidity index was low in three patients with CMV IgM positive (7.14%, n=3). A weak correlation was found between IgG antibody level and age of CMV seropositive pregnant women (p=0.041, ρ=0.038, r2: 0.001). Although the rate of CMV IgG seropositivity changes according to the year, it was lowest (83.22%) in 2016, and CMV IgM positivity was highest in 2019 (2.13%). CMV seropositivity was highest in pregnant women aged 38 - 48 years and CMV IgG levels were significantly lower in this group according to age (p=0.004). Conclusion: In the study, CMV IgG seroprevalence (94.22%) is high among pregnant women in Izmir, but the presence of seronegative and CMV IgM positive pregnant women show that there are still risk pregnancies in terms of congenital CMV infection. With the establishment of an effective national surveillance network, additional measures can be applied in the follow-up of pregnant women by expanding the scope of seroprevalence studies with continuously updated data by region and year.

Özet

Amaç: Bu çalışmada, İzmir ilinde gebelerde sitomegalovirüs (CMV) seroprevalansını belirlemek ve CMV IgG antikor düzeyleri ile birlikte CMV avidite test sonuçlarını yıllara göre değerlendirmek amaçlandı. Yöntem: Ocak 2016-Aralık 2019 tarihleri arasında, üniversite hastanesi mikrobiyoloji laboratuvarında 20. gebelik haftası ve altındaki gebelerin (≥18 yaş) serum örneklerinde kemiluminesan mikropartikül immunoassay yöntemi ile çalışılan CMV IgM, CMV IgG ve CMV IgG avidite test sonuçları retrospektif olarak analiz edildi. Bulgular: Çalışmaya dâhil edilen 3.062 gebenin yaş ortalaması 28.57±5.96 yıl (aralık: 18-48 yaş) idi. CMV IgG ve IgM seropozitiflik oranı sırasıyla %94.22 (n=2885/3062) ve %1.37 (n=42) olarak bulundu. CMV IgM pozitif olan üç hastada CMV IgG avidite indeksi düşük belirlendi (%7.14, n=3). CMV seropozitif gebelerin IgG antikor düzeyi ve yaşları arasında zayıf bir korelasyon ilişkisi saptandı (p=0.041, ρ=0.038, r2=0.001). CMV IgG seropozitiflik oranı yıllara göre değişmekle birlikte, 2016 yılında (%83.22) en düşük düzeyde, CMV IgM pozitiflik oranı ise 2019 yılında (%2.13) en yüksek düzeyde saptandı. CMV seropozitifliği, 38-48 yaş arası gebelerde en yüksek düzeyde saptandı ve yaşa göre bu grupta CMV IgG düzeylerinin anlamlı olarak daha düşük olduğu görüldü (p=0.004). Sonuç: Çalışmada, İzmir ilindeki gebelerde CMV IgG seroprevalansı (%94.22) yüksek seyretmektedir, ancak seronegatif ve CMV IgM pozitif gebelerin de varlığı konjential CMV enfeksiyonu açısından riskli gebeliklerin devam ettiğini göstermektedir. Etkin bir ulusal sürveyans ağının oluşturulmasıyla seroprevalans çalışmalarının kapsamının genişletilerek bölgelere ve yıllara göre sürekli olarak güncellenen verilerle gebe takibinde ek tedbirlerin uygulanması sağlanabilir.

🔖

Cite This Article

Yurtsever, S. G., Kaya, S., Peker, B. O., Müderris, T. (2022). Seroprevalence of Cytomegalovirus (CMV) IgG and IgM Antibodies in Pregnant Women in Izmir: An Analysis of CMV IgG Avidity Tests. Türk Mikrobiyoloji Cemiyeti Dergisi, Cilt: 52 - Sayı: 1, 56–62. https://ajindex.com/articles/635721

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Lazzarotto T, Blázquez-Gamero D, Delforge M-L, et al. Congenital cytomegalovirus infection: A narrative review of the issues in screening and management from a panel of European experts. Front Pediatr. 2020;8:13.
  2. Chiopris G, Veronese P, Cusenza F, et al. Congenital cytomegalovirus infection: Update on diagnosis and treatment. Microorganisms. 2020;8(10):1-17.
  3. Thigpen J. Congenital cytomegalovirus-history, current practice, and future opportunities. Neonatal Netw. 2020;39(5):293-8.
  4. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86- 102.
  5. Sahiner F, Cekmez F, Cetinkaya M, et al. Congenital cytomegalovirus infections and glycoprotein B genotypes in live-born infants: a prevalence study in Turkey. Infect Dis (Lond). 2015;47(7):465-71.
  6. Zeytinoğlu A, Terek D, Arslan A, ve ark. Yenidoğan bebeklerin tükürük örneğinde CMV DNA varlığı ile konjenital CMV enfeksiyonunun araştırılması. Mikrobiyol Bul. 2019;53(1):53-60.
  7. Prince HE, Lapé-Nixon M. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy. Clin Vaccine Immunol. 2014;21(10):1377-84.
  8. Çetinkaya RA. Gebelerde sitomegalovirüs seroprevalansı ve Türkiye’nin dünyadaki seroepidemiyolojik durumu; Bir meta-analiz araştırması. Flora. 2019;24(2):119-30.
  9. Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol. 2008;41(2):57-62.
  10. Revello MG, Fabbri E, Furione M, et al. Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: a 20-year experience. J Clin Virol. 2011;50(4):303-7.
  11. Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis. 2009;49(4):522-8.
  12. Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwid